Pacher, P, Nivorozhkin, A, Szabo, C. Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev
2006; 58: 87–114.
Machado-Vieira, R, Lara, DR, Souza, DO, Kapczinski, F. Therapeutic efficacy of allopurinol in mania associated with hyperuricemia. J Clin Psychopharmacol
2001; 21: 621–2.
Ortiz, R, Ulrich, H, Zarate, CA, Machado-Vieira, R. Purinergic system dysfunction in mood disorders: a key target for developing improved therapeutics. Prog Neuropsychopharmacol Biol Psychiatry
2015; 57: 117–31.
Machado-Vieira, R, Lara, DR, Souza, DO, Kapczinski, F. Purinergic dysfunction in mania: an integrative model. Med Hypotheses
2002; 58: 297–304.
Salvadore, G, Viale, CI, Luckenbaugh, DA, Zanatto, VC, Portela, LV, Souza, DO, et al Increased uric acid levels in drug-naïve subjects with bipolar disorder during a first manic episode. Prog Neuropsychopharmacol Biol Psychiatry
2010; 34: 819–21.
Albert, U, De Cori, D, Aguglia, A, Barbaro, F, Bogetto, F, Maina, G. Increased uric acid levels in bipolar disorder subjects during different phases of illness. J Affect Disord
2015; 173: 170–5.
De Berardis, D, Conti, CM, Campanella, D, Carano, A, Di Giuseppe, B, Valchera, A, et al Evaluation of plasma antioxidant levels during different phases of illness in adult patients with bipolar disorder. J Biol Regul Homeost Agents
2008; 22: 195–200.
Muti, M, Del Grande, C, Musetti, L, Marazziti, D, Turri, M, Cirronis, M, et al Serum uric acid levels and different phases of illness in bipolar I patients treated with lithium. Psychiatry Res
2015; 225: 604–8.
Kesebir, S, Tatldil Yaylac, E, Suner, O, Gultekin, BK. Uric acid levels may be a biological marker for the differentiation of unipolar and bipolar disorder: the role of affective temperament. J Affect Disord
2014; 165: 131–4.
Alda, M. Lithium in the treatment of bipolar disorder: pharmacology and pharmacogenetics. Mol Psychiatry
2015; 20: 661–70.
Shorter, E. The history of lithium therapy. Bipolar Disord
2009; 11 (suppl 2): 4–9.
Hirota, T, Kishi, T. Adenosine hypothesis in schizophrenia and bipolar disorder: a systematic review and meta-analysis of randomized controlled trial of adjuvant purinergic modulators. Schizophr Res
2013; 149: 88–95.
Jahangard, L, Soroush, S, Haghighi, M, Ghaleiha, A, Bajoghli, H, Holsboer-Trachsler, E, et al In a double-blind, randomized and placebo-controlled trial, adjuvant allopurinol improved symptoms of mania in in-patients suffering from bipolar disorder. Eur Neuropsychopharmacol
2014; 24: 1210–21.
Weiser, M, Burshtein, S, Gershon, AA, Marian, G, Vlad, N, Grecu, IG, et al Allopurinol for mania: a randomized trial of allopurinol versus placebo as add-on treatment to mood stabilizers and/or antipsychotic agents in manic patients with bipolar disorder. Bipolar Disord
2014; 16: 441–7.
Sanches, M, Newberg, AR, Soares, JC. Emerging drugs for bipolar disorder. Expert Opin Emerg Drugs
2010; 15: 453–66.
Zarate, CA, Manji, HK. Putative drugs and targets for bipolar disorder. Mt Sinai J Med
2008; 75: 226–47.
Moher, D, Liberati, A, Tetzlaff, J, Altman, DG, The PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med
2009; 6: e1000097.
Young, RC, Biggs, JT, Ziegler, VE, Meyer, DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry
1978; 133: 429–35.
Schunemann, HJ, Oxman, AD, Vist, GE, Higgins, JP, Deeks, JJ, Glasziou, P, et al Interpreting results and drawing conclusions. In Cochrane Handbook for Systematic Reviews of Interventions (eds Higgins, JP, Green, S). Cochrane Collaboration, 2008.
Higgins, JP, Altman, DG, Gotzsche, PC, Juni, P, Moher, D, Oxman, AD, et al The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ
2011; 343: d5928.
Dumville, JC, Torgerson, DJ, Hewitt, CE. Reporting attrition in randomised controlled trials. BMJ
2006; 332: 969–71.
Gupta, SK. Intention-to-treat concept: a review. Perspect Clin Res
2011; 2: 109–12.
Deeks, JJ, Higgins, JP, Altman, DG. Analysing data and undertaking meta-analyses. In Cochrane Handbook for Systematic Reviews of Interventions (eds Higgins, JP, Green, S). Cochrane Collaboration, 2008.
Higgins, JP, Thompson, SG, Deeks, JJ, Altman, DG. Measuring inconsistency in meta-analyses. BMJ
2003; 327: 557–60.
Sterne, JA, Egger, M, Moher, D. Addressing reporting biases. In Cochrane Handbook for Systematic Reviews of Interventions (eds Higgins, JP, Green, S). Cochrane Collaboration, 2008.
Akhondzadeh, S, Milajerdi, MR, Amini, H, Tehrani-Doost, M. Allopurinol as an adjunct to lithium and haloperidol for treatment of patients with acute mania: a double-blind, randomized, placebo-controlled trial. Bipolar Disord
2006; 8: 485–9.
Fan, A, Berg, A, Bresee, C, Glassman, LH, Rapaport, MH. Allopurinol augmentation in the outpatient treatment of bipolar mania: a pilot study. Bipolar Disord
2012; 14: 206–10.
Machado-Vieira, R, Soares, JC, Lara, DR, Luckenbaugh, DA, Busnello, JV, Marca, G, et al A double-blind, randomized, placebo-controlled 4-week study on the efficacy and safety of the purinergic agents allopurinol and dipyridamole adjunctive to lithium in acute bipolar mania. J Clin Psychiatry
2008; 69: 1237–45.
Cohen, J. Statistical Power Analysis for the Behavioral Sciences (2nd edn). Erlbaum, 1988.
Seth, R, Kydd, AS, Buchbinder, R, Bombardier, C, Edwards, CJ. Allopurinol for chronic gout. Cochrane Database Syst Rev
2014; 10: CD006077.
Ketter, TA, Nasrallah, HA, Fagiolini, A. Mood stabilizers and atypical antipsychotics: bimodal treatments for bipolar disorder. Psychopharmacol Bull
2006; 39: 120–46.
Bartoli, F, Crocamo, C, Gennaro, GM, Castagna, G, Trotta, G, Clerici, M, et al Exploring the association between bipolar disorder and uric acid: a mediation analysis. J Psychosom Res
2016; 84: 56–9.